UBT-251 vs Retatrutide: Which One Melts Fat Faster?

Before comparing two drugs, it helps to have the whole map of how this class of compounds works, because the naming conventions are confusing and the differences between them come down to which receptors they hit.

The original weight loss drugs in this family target one receptor, something called GLP-1, which is a gut hormone that gets released when you eat and tells your brain you are full while also slowing how fast food leaves your stomach, and semaglutide does exactly this and nothing more.

Then came the dual agonists, which add a second target called GIP, another gut hormone that works alongside GLP-1 and appears to improve how your fat tissue handles incoming energy. Tirzepatide hits both, and the weight loss numbers roughly doubled compared to single-receptor drugs.

The next generation adds a third receptor, glucagon, which is the hormone your body uses to pull stored energy out of the liver and raise your metabolic rate. Adding glucagon to the mix means you are not only eating less, you are also burning more.

That third target is what makes retatrutide and UBT-251 different from everything that came before them. They are triple agonists, hitting GLP-1, GIP, and glucagon at the same time.

Now, UBT-251, which is Novo Nordisk's version, doesn't have their formulation released to the public. It's still a proprietary blend, but the results that they're seeing so far are pretty significant.

That matters more than it sounds, because with retatrutide the peptide sequence is known, the receptor binding ratios are published, and researchers outside Eli Lilly can model what it does. With UBT-251 you are working from trial outcomes alone, and you do not know how heavily it leans on any one of the three receptors.

Novo Nordisk acquired the compound from a Chinese biotech called United Laboratories in a deal reported around 2 billion dollars, which tells you something about how the data looked internally before it went public.

So, if you look at the phase two trials from Eli Lilly, they did a 48-week trial, which is just about a year.

They scaled people up to 12 milligrams per week, and the average weight that was lost was about 24 percent of their body weight.

That word "scaled" is doing a lot of work in that sentence, since the trial actually began at low doses and stepped up gradually over months rather than starting anyone at the full amount, because the side effects of these drugs are almost entirely dose-dependent and almost entirely gastrointestinal.

Nausea, vomiting, and constipation are what drop people out of these trials, and the rate of those side effects tracks closely with how fast you climb rather than where you end up.

For UBT-251 made by Novo Nordisk, they're doing a 24-week trial, so half of the amount of time, and their subjects are seeing a 19 to 20 percent total body weight loss.

So yes, on paper, people are losing more on retatrutide, but they're on it for twice as long.

Doing the math changes the picture quite a bit. Twenty-four percent over 48 weeks averages out to roughly half a percent of body weight per week. Nineteen to twenty percent over 24 weeks is closer to eight tenths of a percent per week, which puts UBT-251 ahead once you measure it by rate instead of by total.

But weight loss on these drugs does not happen at a constant rate, which is why comparing weekly averages across trials of different lengths is not a clean comparison. The curve is steep at the beginning and flattens out as you go.

Think of it like draining a tank where the water pressure at the outlet depends on how full the tank is. The first weeks empty fast because the pressure is high, and as the tank empties the flow slows down even though nothing about the outlet changed.

The same pattern shows up in the body, where a heavier person has more fat available to mobilize, a higher resting energy expenditure, and a larger gap between what they were eating and what they eat now, so the early losses come quickly.

By month eight or nine, that same person is smaller, burning fewer calories at rest, and has partially adapted to the appetite suppression, so the weekly rate drops even at the same dose.

Which means the 24-week UBT-251 number is capturing the steep part of the curve, and the 48-week retatrutide number is averaging the steep part together with the flat part.

If you ran UBT-251 out to 48 weeks, the second half almost certainly would not deliver another 19 to 20 percent. It would deliver something smaller, and where it lands is the actual open question.

There is a second reason these numbers do not line up cleanly, and it comes down to who was in each trial.

Trial populations differ on starting body mass index, on how many participants had type 2 diabetes, and on what dietary counseling they received alongside the injections. Diabetic participants consistently lose less weight on these drugs than non-diabetic participants, sometimes by a third or more, which is thought to relate to how insulin resistance affects fat mobilization.

So if one trial enrolled a higher proportion of diabetic patients, its headline number sits lower for reasons that have nothing to do with the drug.

None of this is settled by the phase two data, and both compounds are still moving through phase three.

What would actually separate these two drugs is not total pounds lost. It is what those pounds are made of.

Every weight loss intervention costs you some lean mass, and with the earlier GLP-1 drugs the estimates ran around 25 to 40 percent of total weight lost coming from lean tissue, which includes muscle, organ mass, and water.

That is a problem, because muscle is the tissue that burns calories at rest, and losing it lowers the metabolic floor you have to defend once you stop the drug.

The glucagon receptor is the reason triple agonists might behave differently here. Glucagon preferentially drives hepatic lipolysis, meaning it pulls fat out of the liver specifically, and it raises energy expenditure rather than only suppressing intake.

In theory, a drug that increases how much you burn alongside reducing how much you eat should spare more lean tissue than a drug that only reduces intake, because the body is not forced to break down protein to close as large an energy gap.

The body composition data on retatrutide is limited and the data on UBT-251 is more limited still, so treat that as a mechanism that makes sense on paper rather than something the trials have confirmed.

There is also a liver angle worth knowing about. Retatrutide's phase two data showed substantial reductions in liver fat, with many participants going from measurable hepatic steatosis to normal liver fat levels, and that is the glucagon component doing work the other receptors do not do.

Whether UBT-251 matches that depends entirely on its glucagon binding ratio, which is exactly the part of the formulation that has not been made public.

So the honest read is that retatrutide has more data behind it, a known structure, longer trial duration, and published liver outcomes, while UBT-251 has a steeper early loss rate and a much thinner public record.

If you are trying to decide between them based on what is known right now, the amount of published information is the deciding factor, not the percentage in the headline.

What you can actually act on has less to do with which compound you choose and more to do with what you do around it.

Protein intake and resistance training are the two things that shift the ratio of fat to lean tissue lost, and neither of them changes based on which of these drugs you are on. Somewhere around 1.6 grams of protein per kilogram of body weight is where the muscle-sparing benefit shows up in the literature, and lifting two to three times a week gives that protein something to build with.

Without those, both drugs will strip lean mass alongside fat, and the number on the scale will look excellent while the composition underneath it does not.

The comparison everyone wants to make is which one melts fat faster, and the trials as they exist cannot answer that, because one ran twice as long as the other, the populations were not matched, and neither reported the body composition breakdown in detail.

What the trials do tell you is that adding the glucagon receptor moved the ceiling from roughly 20 percent to roughly 24 percent of body weight, and that both companies now believe the third target is worth building around.

The drug is the part that gets easier every year. What you do with the body underneath it stays exactly as hard as it has always been.